Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pimavanserin Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 7:59 PM EDT
Recruiting Phase 2 Interventional

Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
Psilocybin, Pimavanserin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 2, 2026, 7:59 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Psilocybin Efficacy With or Without Pimavanserin Pretreatment

NCT07610135
View directory record Official record
Conditions
Mood (Psychological Function), Well Being, Mood, Healthy
Interventions
Psilocybin, Pimavanserin, Inactive Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 7:59 PM EDT
Recruiting Phase 2 Interventional

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

NCT06592833
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin, Pimavanserin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

NCT02970292
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 2, 2026, 7:59 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

NCT04164758
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Pimavanserin, Placebo, Quetiapine
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

NCT03575052
View directory record Official record
Conditions
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
60 Years and older
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Costa Mesa, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Sep 2, 2026, 7:59 PM EDT
Terminated Phase 2 Interventional Results available

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

NCT02992132
View directory record Official record
Conditions
Agitation and Aggression in Alzheimer's Disease
Interventions
Pimavanserin 34 mg, Pimavanserin 20 mg, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
33
States / cities
Costa Mesa, California • Fresno, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 2, 2026, 7:59 PM EDT
Withdrawn Early Phase 1 Interventional

Pimavanserin for Sleep in Parkinson Disease

NCT05796167
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pimavanserin
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
40 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 2, 2026, 7:59 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

NCT05555615
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 18 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

NCT03018340
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

NCT05523895
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 2, 2026, 7:59 PM EDT
Recruiting Phase 2 Interventional

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

NCT05999240
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID], Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Lawrence, Kansas • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 2 Interventional

ACP-103 to Treat Parkinson's Disease

NCT00086294
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias
Interventions
Intravenous Levodopa, ACP-103
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

NCT03482882
View directory record Official record
Conditions
Treatment of Depression in Adults With Parkinson's Disease (PD)
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Costa Mesa, California • Fountain Valley, California • Pasadena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 2, 2026, 7:59 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

NCT05357612
View directory record Official record
Conditions
Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
Interventions
Pimavanserin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 4 Interventional Results available

Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder

NCT04188392
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Insomnia
Interventions
Pimavanserin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 4 Interventional Results available

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

NCT04292223
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Scottsdale, Arizona • Fullerton, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCT00550238
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
83
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 2, 2026, 7:59 PM EDT
Recruiting Phase 2 Interventional

Pimavanserin for Insomnia in Veterans With PTSD

NCT05441280
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Insomnia
Interventions
pimavanserin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 2, 2026, 7:59 PM EDT
Recruiting Phase 4 Interventional

Comparing Antipsychotic Medications in LBD Over Time

NCT05590637
View directory record Official record
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT03968159
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 2, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

NCT01518309
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 2, 2026, 7:59 PM EDT
Terminated Phase 3 Interventional Results available

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT04000009
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Garden Grove, California • Glendale, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 2, 2026, 7:59 PM EDT